Challenge
In 2014, a multinational pharmaceutical company introduced a prescription drug to the Hong Kong market. This drug had proven to be of significant clinical benefit but was categorized as a self-financed item (SFI) and was not yet covered by government hospitals as a tender item.
In the first two years after the introduction of the drug, part of the sales and distribution were carried out by another party. However, sales results were not satisfying. In 2015, trade sales activities were outsourced to DKSH because of our good track record, broad reach and long-standing relationships with pharmacists.